{"id":1704,"date":"2019-08-01T09:44:15","date_gmt":"2019-08-01T09:44:15","guid":{"rendered":"https:\/\/aspree.org\/usa\/?p=1704"},"modified":"2021-09-07T13:01:47","modified_gmt":"2021-09-07T13:01:47","slug":"nih-funds-follow-up-observational-study-aspree-xt-extension","status":"publish","type":"post","link":"https:\/\/aspree.org\/usa\/nih-funds-follow-up-observational-study-aspree-xt-extension\/","title":{"rendered":"ASPREE-XT (eXTension) study funded to determine longer-term effects of aspirin on health"},"content":{"rendered":"<h1><strong>Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly<\/strong><\/h1>\n<p><em>ANNOUNCEMENT:<\/em><\/p>\n<ul>\n<li>Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin.<\/li>\n<li>ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of ASPREE (low dose aspirin vs placebo) in 2017.<\/li>\n<li>Researchers will continue to monitor for cancer, dementia, cardiovascular health, physical disability, depression and frailty.<\/li>\n<li>ASPREE-XT will also investigate the impact that medical conditions, lifestyle, the environment and genetics have on health and aging.<\/li>\n<li>More than 15,000 study participants in the US and Australia.<\/li>\n<\/ul>\n<p>Researchers at the US-based <a href=\"http:\/\/bermancenter.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Berman Center for Outcomes and Clinical Research<\/a>, part of the <a href=\"https:\/\/www.hhrinstitute.org\/aspree-study-a-game-changer-at-the-cutting-edge-of-medicine\/\" target=\"_blank\" rel=\"noopener noreferrer\">Hennepin Healthcare Research Institute<\/a>, and Monash University in Australia, are expanding on the landmark aspirin trial, ASPREE, with a five-year follow up study to investigate the long-term effects of low dose aspirin on the health of older people.<\/p>\n<p>The world-first <a href=\"\/usa\/about-the-aspree-project\/\" rel=\"noopener noreferrer\">ASPREE-XT (eXTension) study<\/a> will track the health of more than 15,000 participants in the US and Australia, following an average period of almost five years on daily low dose aspirin or a placebo tablet in the ASPREE trial.<\/p>\n<p><a href=\"\/usa\/about-us\/\">Researchers<\/a> will assess health impacts after prolonged aspirin use on cancer, dementia, cardiovascular health, physical disability, depression and other aspects of aging including frailty.<\/p>\n<p>ASPREE-XT also aims to identify the impact that medical conditions, lifestyle, the environment and genetics have on health and aging, providing an unprecedented window into an aging population.<\/p>\n<p>Principal investigator in Australia, Professor John McNeil, said ASPREE-XT would contribute high quality research to understand factors that affect quality of life and independence for older people.<\/p>\n<p>\u201cASPREE-XT builds on many millions of individual items of health data collected in the ASPREE study, providing a rare opportunity to investigate the effects of aspirin and other factors on the health of older people,\u201d Professor McNeil said.<\/p>\n<p>\u201cImportantly, ASPREE-XT will also help identify factors that contribute to onset of disease in older people and explain why some people become frail and disabled while others do not.\u201d<\/p>\n<p>Professor McNeil said ASPREE-XT will be one of the largest observational studies conducted in Australia with the help of over 2000 general practitioners across south-eastern Australia.<\/p>\n<p>\u201cLife-expectancy has increased globally and ASPREE-XT will continue to answer questions of daily relevance for GPs caring for their older patients,\u201d Professor McNeil said.<\/p>\n<p>\u201cThe collection of this important health information is of great benefit to society, and through ASPREE-XT we are grateful that our participants continue to contribute data.\u201d<\/p>\n<p>ASPREE-XT is <a href=\"\/usa\/funding-and-collaborators\/\">funded<\/a> by the US National Institutes of Health.<\/p>\n<p>Read the Hennepin Healthcare Research Institute media release <a href=\"https:\/\/www.hhrinstitute.org\/aspree-xt-extension-study-receives-42-3-million-to-determine-longer-term-effects-of-aspirin-on-health\/\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<p>ASPREE was a world-first clinical trial of low-dose aspirin for primary prevention in the elderly. <a href=\"\/usa\/publications\/\">Trial findings<\/a> published in the New England Journal of Medicine in September 2018, were adopted into the American College of Cardiology\/American Heart Association aspirin guidelines in March 2019.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly ANNOUNCEMENT: Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin. ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of ASPREE (low dose [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[13,15,16],"tags":[42,43],"_links":{"self":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/1704"}],"collection":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/comments?post=1704"}],"version-history":[{"count":6,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/1704\/revisions"}],"predecessor-version":[{"id":2173,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/1704\/revisions\/2173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/media\/1705"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/media?parent=1704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/categories?post=1704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/tags?post=1704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}